Q2 2026 landed a beat-and-raise (4 Aug) and cleared the earnings gate; signals are unchanged and confidence is restored — at a 2% lower price. Revenue $16.6bn beat consensus, KEYTRUDA grew +4% to $8.4bn and subcutaneous QLEX ramped $128m -> $463m, and Merck raised FY revenue and EPS guidance. A $2.43/sh Terns acquisition IPR&D charge deepened the (deflationary) GAAP distortion, but the clean/forward earnings case is intact.
Merck & Co. is one of the world's largest research-driven pharmaceutical companies, built around two divisions: human-health Pharmaceuticals (oncology, vaccines, hospital, cardio-metabolic, infectious disease) and Animal Health. Its defining asset is KEYTRUDA, the anti-PD-1 immuno-oncology drug that is the best-selling medicine in the world and runs at roughly an $8.4bn-a-quarter pace across a widening set of cancers. What sets Merck apart is the depth of that oncology franchise plus a large, cash-generative vaccine business (Gardasil, pneumococcal, measles/mumps) and a resilient Animal Health arm. The strategic question that dominates the stock is concentration: KEYTRUDA is roughly 40-45% of pharma revenue and its main US patents expire in 2028, so the entire investment case turns on whether the pipeline and a new subcutaneous KEYTRUDA formulation can backfill that cliff.
Lifecycle & sector: Mature large-cap pharma. Scored on the Healthcare/Pharma profile — R&D efficiency, pipeline depth/stage, patent-cliff exposure, revenue durability, ROIC — not on growth-stage metrics.
| Sub-signal | Reading (Q2 2026, reported 4 Aug) | Score |
|---|---|---|
| Revenue trajectory | Q2 sales $16.6bn, +5% YoY, ahead of $16.41bn consensus. FY guide raised to $66.3-67.3bn (+2-4%). Modest but positive, firming vs a soft H1. | 62 |
| Profitability (clean) | Clean operating margin ~28% (ex acquired-IPR&D); gross margin ~76%. Among the best in large-cap pharma. Reported margins are noise this year. | 78 |
| Cash generation | TTM operating-cash-flow margin ~27%; FCF/share ~$5.7; clean FCF yield ~5-6%. Comfortably funds the dividend (~38% clean payout) and buybacks. | 74 |
| Balance-sheet health | Interest coverage ~17x, current ratio 1.30, Net-debt/clean-EBITDA <2x. Terns added modest debt; leverage stays conservative. | 72 |
| Revenue durability / concentration | The weak leg: KEYTRUDA ~40-45% of pharma revenue, US LOE 2028. Winrevair, QLEX, Gardasil (China still soft), Animal Health diversify but don't yet offset the cliff. | 52 |
Moat score: 63/100 — a real but eroding-at-a-date moat. Switching-cost and cost-advantage sub-scores are derived from the Competitive Environment read below, not asserted.
| Rival / threat | Type | Share trajectory vs MRK | Moat-erosion vector |
|---|---|---|---|
| Pembrolizumab biosimilars (7+ filers) | Direct copy at LOE | Stable now; sharp share loss expected from 2028 | Price + formulary substitution once IV KEYTRUDA loses exclusivity |
| Summit/Akeso ivonescimab | Next-gen bispecific (PD-1/VEGF) | MRK leading; ivonescimab gaining mind-share in 1L NSCLC data | Efficacy parity/superiority could displace KEYTRUDA in key lung indications |
| Bristol Myers (Opdivo/Opdualag) | Direct IO rival | Roughly stable; KEYTRUDA remains category leader | Indication-by-indication share competition |
| AstraZeneca / Pfizer / Roche (IO + ADC) | Direct + combination | Stable; MRK ahead on breadth | Combo regimens and ADCs chipping at niches |
Net effect on the moat: Switching Costs trimmed to 58 and the durability sub-signal to 52 to reflect the dated reset; QLEX is the one vector improving stickiness. Overall competitive threat elevated — structural and dated, not a present-tape crisis.
ROIC & capital allocation: 70/100. Clean ROIC comfortably above cost of capital; disciplined bolt-on M&A (Verona, Cidara, Terns) aimed at the post-2028 gap; steadily rising dividend (+5% to $0.85/qtr) at a conservative ~38% clean payout. The risk is that the acquired-IPR&D bill keeps depressing reported earnings while the payoff is years out.
| Metric | Value | Read |
|---|---|---|
| Clean forward P/E (on ~$9.0) | ~14.3x ($128.37 / $9.0) | Attractive — below sector and below warranted |
| Forward P/E (consensus $9.6) | ~13.4x | Cheaper still on the Street's number |
| Reported TTM P/E | 36x (FMP) / ~103x (Yahoo) | Distorted by IPR&D — ignore |
| FCF yield (clean) | ~5-6% | Attractive; funds dividend + buyback |
| Dividend yield | 2.65% ($3.40 fwd; $3.36 TTM) | Raised +5% to $0.85/qtr; ~38% clean payout |
| Own 5-yr valuation decile | ~3rd decile | Toward the cheap end of its own history |
| PEG (clean) | ~2.4 | Low growth is the offset to the low multiple |
| Analyst consensus (n=37 / 26) | Value | vs $128.37 |
|---|---|---|
| Consensus target (FMP) | $140.64 | +9.6% |
| Median target | $146 | +13.7% |
| High / Low | $155 / $105 | +21% / -18% |
| Grades distribution | 25 Buy · 11 Hold · 1 Sell (Buy consensus, 68% bullish) | No downgrades post-Q2; Guggenheim reiterated Buy 5 Aug |
| FMP health rating | B (3/5): ROE 5, DCF 4, ROA 4 strong; P/E 2, P/B 1, D/E 1 weak | Weak sub-scores are the IPR&D-distorted P/E and book — consistent with our clean adjustment |
Primary driver: the race between Merck's pipeline/subcutaneous backfill and the 2028 KEYTRUDA loss-of-exclusivity, overlaid with IRA/drug-pricing policy. A company-specific structural driver rather than a macro commodity, so there is no commodity-trend overlay.
| Horizon | Assessment | Read |
|---|---|---|
| Historical (12-24m) | KEYTRUDA kept growing; Winrevair launched well; but Gardasil China collapsed (~-39%) and the cliff moved into focus. Mixed. | Neutral |
| Current | Q2 beat-and-raise; KEYTRUDA +4% to $8.4bn; QLEX $463m (up 3.6x QoQ); pipeline Breakthrough win. Positive, but the cliff and IRA are unmoved. | Neutral (56) |
| Forward (6-12m) | Consensus sees revenue +2-4% and clean EPS ~$9.6; the 2028 step-down still looms. Optionality (QLEX/Terns/Winrevair) is upside, not base case. | Neutral |
Driver score 55/100 — Neutral. Below the 65 tailwind threshold, so it does not amplify the base signal on any horizon (a BUY stays a BUY, not STRONG BUY). The QLEX ramp is the one thing pushing the needle up vs a flat read.
Read from the 30 Jul 2026 Macro-Economic report's Driver-Sector matrix: Health Care (XLV) is Neutral short, Neutral medium, Outperform long. Anchoring on the medium horizon, economic pressure is Neutral — so it does not enable a STRONG-BUY amplification (which in any case can't fire while the driver is 55). The constructive note is the long-horizon Outperform: in the report's stagflation-lite / energy-shock-re-armed regime, low-beta (0.21) defensive pharma with a covered dividend carries a bid, and MRK could benefit from any rotation out of the concentrated AI mega-cap complex (the report's armed 'S&P concentration / AI earnings-quality unwind' tail — which MRK does NOT belong to: it is cheap, defensive, non-AI). Corrected from last report's carried-forward 'Tailwind/65', which was inferred rather than read from the matrix.
Source: sector-map (XLV: Short N · Medium N · Long O) · Macro report 2026-07-30
Risk-reward. The multi-timeframe trend is bullish everywhere (monthly/weekly/daily all uptrend, daily strong-uptrend, confluence strongly bullish). But the stock ran to a 52-wk high $135.05 on 27 Jul and has since pulled back to ~$128, cooling the daily RSI to 53.9 and rolling the daily MACD histogram slightly negative. Post-Q2 (beat-and-raise) the reaction was muted/flat — a mild sell-the-news after the run. So the direction is up but the entry is mid-range: a logical stop sits at ~$118 (below the rising SMA50 123.7 and the June breakout), a wide ~2.5+ ATR stop from here. Risk-reward score ~47.
Relative strength. Very strong — ~+65% off the 52-wk low $77.58, comfortably above the SMA200 ($112.5), an out-performer within a defensive sector that itself carries a long-horizon Outperform.
Macro overlay (10% weight). Low macro sensitivity. Hot ISM services prices (70.3) and a stagflation-lite regime modestly favour defensives; rates ticked down (10-Y 4.69 -> 4.63) — a small positive for a bond-proxy defensive.
Sentiment. Analyst grades all maintain over the last month (0 upgrades / 0 downgrades; Guggenheim reiterated Buy 5 Aug post-print); news flow neutral-to-positive (repeatedly cited as a core SCHD/dividend holding; KEYTRUDA the revenue leader across oncology-market notes). No negative estimate-revision momentum — estimates edged up on the raise.
Catalysts. Calm calendar: Q2 is done; next earnings 29 Oct. Catalyst-clustering score ~70 — no event risk in the window, supporting a normal position size but removing any near-term spark.
| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| 2026-08-07 | Nonfarm Payrolls + Unemployment (Jul) | High | +80k / 4.2% | +57k / 4.2% | Market-wide | Low direct MRK relevance; sets risk-on/off tape for defensives |
| 2026-08-12 | CPI / Core CPI (Jul) | High | 3.4% / 2.5% YoY | 3.5% / 2.6% | Market-wide | Rate-path input; matters to MRK only as a bond-proxy defensive |
| 2026-08-19 | FOMC Minutes | High | — | — | Market-wide | Rate-path colour; low direct MRK impact |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-08-03 | ISM Manufacturing PMI (Jul) | 55.6 | 54.0 | +3.0% above | Mild risk-on; neutral for MRK |
| 2026-08-05 | ISM Services Prices (Jul) | 70.3 | 65.0 | +8.2% above | Hot — stagflation signal; modestly favours defensives |
| 2026-08-04 | JOLTS Job Openings (Jun) | 7.359m | 7.4m | -0.6% below | Softening labour; neutral for MRK |
Merck is a low-macro-sensitivity name; no high-impact economic release directly moves it. The one MRK-specific event — Q2 earnings — has passed (4 Aug, beat-and-raise). The genuine sector risk (IRA/Medicare drug-price negotiation) is a policy overhang, not a calendar item. The macro backdrop (hot services prices, stagflation-lite, rates easing slightly) is a mild net positive for a defensive dividend payer.
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend | Bullish | 63.7 | + rising | S: 99.1 / R: 134.6 | Resistance breakout | 0.15x |
| Weekly | Uptrend | Bullish | 60.0 | + flat | S: 106.0 / R: 125.1 | Resistance breakout | 0.87x |
| Daily | Strong uptrend | Bullish (momentum cooling) | 53.9 | - hist falling | S: 123.7 / R: 131.7 / 135.05 | Above breakout, pulled back | 0.79x |
| Hourly | Uptrend | Neutral | 56.5 | flat | S: 127.8 / R: 131.1 | — | n/a |
| 15-min | Uptrend | Neutral | 60.5 | turning up | S: 127.8 / R: 129.6 | — | n/a |
| Confluence: Strongly Bullish (trend) — but no clean near-term entry · MTF Score 72 | |||||||
Every timeframe is in an uptrend and the daily is a strong uptrend above a rising SMA50 (123.7) and well above the SMA200 (112.5) — the primary trend is unambiguously up. The nuance is timing: price pulled back ~5% from the 27-Jul high of 135.05, daily RSI cooled to the low-50s and the daily MACD histogram turned slightly negative, so momentum is consolidating rather than accelerating. The textbook read is higher-timeframe uptrend, daily digesting a gain — constructive for medium/long entries, but the short-term lacks a volume-backed break or a tested support bounce. Levels: a volume-backed reclaim of 131.7 -> 135 confirms; a pullback into 123.7 (SMA50) is the higher-conviction add zone; the case weakens below ~118.
MRK 6-month daily with SMA50. Steady climb from ~$110 (Apr) to a 52-wk high $135 (27 Jul), then a ~5% digestion to ~$128 through the 4-Aug beat-and-raise. Primary uptrend intact; near-term consolidating.
QLEX subcutaneous keeps ramping and clearly extends the KEYTRUDA franchise past the 2028 IV cliff; Winrevair scales, calderasib/Terns pipeline delivers, biosimilar/ivonescimab fears recede. Clean EPS pushes to ~$10 and the multiple re-rates toward 16-17x. = the Street's high target and roughly the raised-guidance-plus-pipeline case.
Beat-and-raise trajectory continues: ~$9-9.6 clean EPS, revenue +2-4%, dividend growing. The market pays ~15x clean earnings — roughly consensus ($140.64) / median ($146). The 2028 cliff stays a known, priced overhang rather than an imminent shock.
COMPETITIVE trigger: ivonescimab 1L-NSCLC data and the 2028 biosimilar wave intensify erosion fears; a guidance disappointment or harsher IRA outcome compounds it. The multiple compresses to ~11-12x on ~$9 clean EPS. This is the driver flipping to Headwind — the thesis-invalidation floor.
Probability-weighted 12-month fair value ≈ $137 (0.25×155 + 0.50×143 + 0.25×108), a touch above the current $128 and in line with consensus. The distribution is roughly symmetric around a base that itself sits above spot — the reward edge is modest, the cliff is the fat left tail.
Forecast: FUNDAMENTAL is already met (cheap on clean earnings). TECHNICAL: a volume-backed reclaim of 131.7 is ~2-4 weeks away if the uptrend resumes (Moderate confidence); the higher-conviction add is a pullback into the SMA50 ~123.7, plausible on any market wobble (Moderate). CATALYST: none until Q3 earnings 29 Oct (Unlikely to fire before then). Net: the Short stays Buy-on-confirmation until Technical prints; Medium/Long are actionable now on the Fundamental path with staggered entries.
Forecast: Stop unlikely in the next 4-6 weeks — $118 is ~8% below spot and below the rising SMA50; it would take a broad de-rating or a competitive shock. Thesis-invalidation is a 2027-28 watch, not a live 2026 risk. Profit-trim only becomes relevant on a fast run to $146+.
What you're risking: the near-term entry isn't confirmed — you'd be buying mid-range, ~5% under the 52-wk high, into cooling daily momentum with no volume-backed break. The real tail is the 2028 KEYTRUDA cliff (bear $108, -16%). The hard stop is ~8% down at $118.
What you're gaining: a genuinely high-quality franchise at ~14x clean forward earnings (~0.80x its warranted multiple), a growing 2.65% dividend at a safe ~38% clean payout, and several free call options (QLEX, Winrevair, Terns/obesity). You start capturing the ~11% base-case upside immediately.
Read: for a medium/long holder the deal is fair-to-good now on the Fundamental path — scale in and add on a pullback to the SMA50 (~$124) or a volume-backed break of $131.7. For a short-term trader, waiting for that confirmation materially improves the entry.
What you're giving up: a name trading below fair value on clean earnings with analysts at $140-146; you'd be selling into an intact uptrend and forgoing the QLEX/Winrevair/obesity optionality.
What you're protecting: nothing is mechanically triggering an exit right now — no stop hit, no profit-target, no thesis break. The only reason to lighten is if you specifically want less 2028-cliff exposure ahead of the biosimilar wave.
Read: this is a hold/accumulate zone, not a sell zone. No exit rule is live.
{
"ticker": "MRK",
"exchange_ticker": "NYSE:MRK",
"isin": "US58933Y1055",
"country_table": "US",
"date": "2026-08-07",
"version": "v6",
"prior_report": "MRK_Signal_v6_20260725_1641.html",
"analysis_status": "on-going",
"finder_ticker": "MRK",
"finder_exchange": "\ud83c\uddfa\ud83c\uddf8 NYSE",
"section": "Defensive Health Care",
"user_context": {
"horizon": "all",
"allocation_pct": null,
"portfolio_role": null
},
"user_horizon": null,
"user_allocation_pct": null,
"portfolio_role": null,
"sector": "Healthcare / Pharma (Mature)",
"lifecycle_stage": "mature",
"currency": "USD",
"company": "Merck & Co., Inc.",
"brand": "",
"price_at_rating": 128.37,
"signal_short": "HOLD",
"signal_medium": "BUY",
"signal_long": "BUY",
"primary_signal": "BUY",
"short_entry_confirmed": false,
"short_hold_reason": "technical_pending",
"short_cap_reason": "Short base signal is BUY (High Quality + Attractive Valuation + Improving timing), but it fires on the Fundamental group alone \u2014 Technical and Catalyst groups both UNMET (no volume-backed break of 131.7, not a tested SMA50 bounce; post-Q2 24h move was flat, not >+5%). Capped to Buy-on-confirmation: a volume-backed reclaim of 131.7 or a pullback into the 123.7 SMA50 with a higher low.",
"quality_score": 68,
"valuation_score": 68,
"timing_score": 57,
"driver_score": 55,
"driver_label": "Neutral",
"driver_name": "Pipeline build-out vs. Keytruda patent cliff (2028 LOE + IRA)",
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 58,
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map (XLV S=N/M=N/L=O)",
"macro_report_date": "2026-07-30",
"amplification_fired": false,
"quality_detail": {
"industry_benchmark_name": "R&D Efficiency + Patent Cliff",
"industry_benchmark_value": "Keytruda ~40-45% of pharma revenue, US LOE 2028; QLEX subQ ramping",
"industry_benchmark_score": 57,
"moat_score": 63,
"roic_capital_score": 70,
"keytruda_q2_2026_sales_usd_b": 8.4,
"keytruda_qlex_q2_2026_sales_usd_m": 463,
"keytruda_qlex_q1_2026_sales_usd_m": 128,
"q2_2026_revenue_usd_b": 16.6
},
"valuation_detail": {
"clean_fwd_pe": 14.3,
"clean_fwd_pe_on_consensus": 13.4,
"reported_ttm_pe": 36.1,
"clean_eps_runrate": 9.0,
"analyst_fwd_eps": 9.6,
"fy2026_nongaap_eps_guide": "2.66-2.76",
"fy2026_iprd_charges_per_sh": "~5.5-6.0 (Q1 Cidara/Verona ~3.0-3.4 + Q2 Terns 2.43)",
"fcf_yield_reported": 4.5,
"fcf_yield_clean": 5.5,
"dividend_yield": 2.65,
"payout_on_clean_eps_pct": 38,
"consensus_growth_rate": 6.0,
"historical_valuation_decile": 3
},
"warranted_multiple": 17.9,
"actual_multiple": 14.3,
"val_multiple_basis": "clean forward P/E (~$9.0 normalised run-rate)",
"discount_rate_r": 9.13,
"risk_free_10y": 4.63,
"g_near": 4.5,
"g_term": 3.0,
"warranted_ratio": 0.8,
"val_band": "attractive",
"nonop_pct_of_net_income": 100,
"clean_pe": 14.3,
"clean_peg": 2.4,
"competitive_share_trajectory": "stable-now-at-risk-2028",
"competitive_threat_level": "elevated",
"competitive_rivals": [
"pembrolizumab biosimilars (7+ filers)",
"Summit/Akeso ivonescimab",
"Bristol Myers (BMY)",
"AstraZeneca (AZN)",
"Pfizer (PFE)"
],
"timing_detail": {
"mtf_confluence": 72,
"risk_reward_score": 47,
"relative_strength": "very strong (+65% off 52wk low; above SMA200; pulled back ~5% from 52wk high)",
"catalyst_clustering_score": 70,
"breakout_volume_ratio": 0.79,
"dynamic_macro_weight": 0.1
},
"analyst_consensus_target": 140.64,
"analyst_target_high": 155,
"analyst_target_low": 105,
"analyst_target_median": 146,
"analyst_target_upside_pct": 9.6,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 67.6,
"analyst_coverage_count": 37,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"fmp_rating": "B",
"fmp_overall_score": 3,
"overall_confidence": 58,
"confidence_short": 58,
"confidence_medium": 66,
"confidence_long": 70,
"fair_value_est": 143,
"stop_loss": 118,
"target_price": 143,
"scenario_bull": 155,
"scenario_base": 143,
"scenario_bear": 108,
"scenario_bull_target": 155,
"scenario_base_target": 143,
"scenario_bear_target": 108,
"scenario_prob_bull": 25,
"scenario_prob_base": 50,
"scenario_prob_bear": 25,
"hard_gate_state": "caution",
"gates_triggered": [],
"gates_caution": [
"accounting_iprd_charge_distortion",
"keytruda_concentration_patent_cliff",
"drug_pricing_ira"
],
"gates_cleared_this_run": [
"earnings_event_risk_q2_aug4"
],
"do_not_buy_triggers": [],
"gates_callout": "clear with caution \u2014 earnings-event gate CLEARED (Q2 out, beat-and-raise); IPR&D-distorted GAAP scored clean; Keytruda 2028 cliff + IRA scored headwinds; no DNB trigger",
"entry_groups_met": 1,
"entry_criteria_met": 1,
"entry_criteria_total": 3,
"entry_conviction": "Half-Size",
"exit_groups_live": 0,
"exit_criteria_met": 0,
"exit_criteria_total": 3,
"exit_action": "Hold",
"thesis_invalidation_floor": "Keytruda biosimilar/ivonescimab erosion from 2028 outpaces the pipeline + subcutaneous-QLEX backfill so total revenue is set to decline through 2028-29, and/or a full-year guidance cut or harsher-than-expected IRA outcome \u2014 driver flips to Headwind and the case breaks.",
"next_update_date": "2026-08-21",
"next_check_date": "2026-08-21",
"next_update_basis": "default +14d (Q3 earnings 2026-10-29 beyond the 14-day window; the 14d refresh runs first and re-schedules once earnings enters the window)",
"report_filename": "MRK_Signal_v6_20260807_0410.html"
}
Signals unchanged vs 25 Jul (Short HOLD / Medium BUY / Long BUY, primary BUY). The material change is the Q2 beat-and-raise removing the earnings-event gate and restoring confidence, at a 2% lower price. Valuation stays Attractive (ratio ~0.80). Economic-alignment corrected to Neutral (read from the macro XLV matrix S/N/O).